Background
==========

Pancreatic adenocarcinoma is the fourth leading cause of cancer deaths in the United States [@b1]. The annual incidence of pancreatic cancer is rising with approximately 46,420 new cases and nearly 39,590 patient deaths in 2014 [@b2]. Without any substantive improvement in curative therapies, it is anticipated to be the second leading cause of cancer deaths by 2030 [@b3]. Surgical resection is currently the only treatment option that offers the potential of long-term survival. However, only 20% of patients with pancreatic cancer are candidates for resection. Another 30--40% of patients have locally advanced or unresectable pancreatic cancer without measurable metastatic disease. For this group, chemotherapy with radiotherapy (chemoRT) was established as the standard of care over radiation or chemotherapy alone a few decades ago by the Gastrointestinal Tumor Study Group (GITSG) [@b4],[@b5]. For these patients, chemotherapy with radiation is palliative in nature with a median survival of 8--12 months and virtually no long-term survivors [@b6],[@b7]. Of the patients that present with resectable disease, surgical resection provides a 5-year survival of approximately 20%. This article focuses on the recent advances made in combined modality treatment of early stage resectable and borderline-resectable pancreatic adenocarcinoma with the goal of making a compelling case for a multidisciplinary, collaborative, and neoadjuvant approach for optimal outcomes. This strategy also facilitates an ideal clinical research platform capable of rapidly assessing the efficacy of novel therapeutic agents.

Role of Adjuvant Therapy in Pancreatic Cancer
=============================================

Despite improvements in surgical techniques that allow more patients to undergo successful R0 resection, the prognosis even for small tumors without nodal involvement remains poor due to progressive systemic disease. In an effort to improve long-term survival after surgical resection, adjuvant therapy has been studied in various combinations. In 1985, the GITSG conducted a trial that was one of the first to show the benefit of adjuvant therapy by demonstrating that 5-Fluorouracil (5-FU) combined with radiotherapy (RT) after surgical resection led to improved survival compared to observation (2-year survival 42% vs. 15%; *P* = 0.03) [@b8]. The EORTC 40891 trial similarly compared 5-FU-based chemoRT to observation after surgical resection of pancreatic and periampullary adenocarcinoma with median overall survival (OS) of 24.5 versus 19 months (*P* = 0.21) [@b9]. One of the major criticisms of the latter study was that it included periampullary adenocarcinomas, which have a better prognosis compared to pancreatic ductal adenocarcinomas. The rationale for adjuvant chemoRT was established with these early studies.

The role of adjuvant chemoRT was subsequently called into question in the European ESPAC-1 trial [@b10]. Following surgical resection, patients were randomized to either receive 5-FU-based chemotherapy, 5-FU-based chemoRT, both or no treatment following surgical resection. Results were analyzed (in a two-by-two factorial design) based on groups having received chemotherapy or not and those having received chemoRT or not. Median OS in the chemotherapy group was 20.1 versus 15.5 months in the no chemotherapy group (*P* = 0.009). However, in the chemoRT analysis, the median OS was worse at 15.9 months compared to 17.9 months in patients who did not receive chemoRT (*P* = 0.05). This controversial trial is criticized for the lack of radiation quality control, use of outdated radiotherapy delivery techniques, no central review of radiographic response and poor compliance to subscribed treatment. Such limitations confound the ability to accurately and conclusively interpret the results. Nevertheless, the utilization of adjuvant chemoRT remains common in the United States with the benefit of this approach continuing to be actively investigated.

Subsequent European adjuvant clinical trials focused on the relative value of adjuvant chemotherapy rather than chemoRT. In the CONKO-1 trial, patients with resected pancreatic cancer were randomly assigned to either receive six cycles of gemcitabine or observation [@b11]. The use of adjuvant gemcitabine resulted in significant gains in disease-free survival (DFS) from 6.7 to 13.4 months (*P* \< 0.001) and a significant, albeit small, improvement in OS from 20.2 to 22.8 months (*P* = 0.01). Following this trial, the ESPAC-3 study compared adjuvant gemcitabine to 5-FU-based chemotherapy for 6 months [@b12]. Median OS was not statistically different between the two treatment groups (23.6 vs. 23 months; *P* = NS). The overall rates of serious adverse events were significant reduced in the gemcitabine group (7.5%) compared to 5-FU-based treatment (7.5% vs. 14%; *P* \< 0.001), with the toxicity profile also favoring gemcitabine with less stomatitis and diarrhea but more myelosuppression.

In the United States, the incorporation of adjuvant chemoRT continues to be investigated with trials designed to determine the optimal chemotherapy agents and sequencing for use in combination with radiotherapy. The RTOG 97-04 trial compared gemcitabine to 5-FU in a sequential combination of systemic chemotherapy (gemcitabine vs. 5-FU) for 3 weeks followed by 5-FU-based chemoRT and then 3 months of chemotherapy with the same previously used agent. Median OS was 20.5 months for gemcitabine versus 16.9 months for 5-FU (*P* = 0.09) [@b13]. The above trials suggest that whether combined with radiation or not, gemcitabine may be a preferred agent in the adjuvant setting given a better side-effect profile; whereas 5-FU remains the next best option.

Adjuvant Versus Neoadjuvant Debate
==================================

Despite the noted improvements in survival with the addition of adjuvant therapy, the 5-year OS still averages 20% in patients who undergo curative treatment, leaving significant opportunities for improvement. This has led to an increasing interest to incorporate chemotherapy and/or radiation therapy into the neoadjuvant setting. Neoadjuvant treatment may have several advantages over adjuvant therapy (Table[1](#tbl1){ref-type="table"}). First, as the vast majority of patients who undergo complete surgical resection still succumb to distant relapse, delivery of systemic treatment earlier in the disease course; particularly, when the anatomy and vasculature have not yet been disrupted by surgery, might lead to improved treatment effect. Second, almost 30--40% of postoperative patients do not receive any adjuvant therapy either secondary to surgical complications and delayed recovery or patient refusal [@b14]. Third, tumor downstaging resulting from effective neoadjuvant treatment could lead to more effective R0 (complete) resections, which has been shown to be a predictor of survival [@b15]. However, tumor downstaging requires accurate confirmation of the clinical stage prior to initiation of therapy, which is limited by the accuracy of current imaging modalities. Finally, the neoadjuvant platform is perhaps the most efficient *in vivo* model to test novel therapies as the treatment period is finite and pre/posttreatment tissue collection allows for a variety of molecular analyses to gain further insight into tumor biology and mechanisms of resistance. Opponents of neoadjuvant treatment voice concerns that the use of preoperative therapy can lead to a missed window of opportunity for surgical resection, which is the only potentially curative treatment. Such missed opportunities can result from progression of disease (typically distant metastases) or a decline in performance status from treatment toxicities or cancer cachexia. However, the issue of disease progression can also be seen as a paradoxical benefit given the morbidity of a major operative procedure such as pancreaticoduodenectomy in a patient with a biologically aggressive disease that might have likely relapsed soon after surgery. However, delaying surgical resection due to performance status decline from treatment side effects remains a legitimate concern. While no phase III trials exist, several retrospective series, prospective phase II, and systematic reviews have been published which provide some data with regards to neoadjuvant therapy outcomes.

###### 

Potential advantages and disadvantages of neoadjuvant treatment in pancreatic adenocarcinoma

  Neoadjuvant treatment                                                   
  ----------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------
  Intact tumor vasculature not disrupted by surgery                       Progression of disease during neoadjuvant treatment leading to missed window of opportunity for resection
  Early treatment of micrometastatic disease                              Toxicity from neoadjuvant treatment precluding definitive surgical resection
  Ensures delivery of systemic treatment                                  Need tissue confirmation of neoplastic process
  Improved RO resection rate; especially in borderline-resectable cases   
  Ideal in vivo platform for research                                     

Neoadjuvant Treatment of Pancreatic Cancer
==========================================

The concept of incorporating neoadjuvant therapy into pancreatic cancer management started soon after early studies demonstrated a benefit of adjuvant treatment as compared to surgery alone. As early as 1980, Pipelich et al. showed that preoperative radiotherapy was not only feasible but allowed for downstaging of primary tumors and thus successful surgical resection [@b16]. Since then, various combinations of chemotherapy, chemoRT or induction chemotherapy followed by chemoRT have been studied in relatively small phase I--II trials.

Early studies focused on 5-FU-based treatment combinations. The combination of 5-FU and mitomycin C (MMC) with external beam radiotherapy (EBRT) was particularly popular at that time. This was in part related to the widespread availability of the agents and their well-established role as potent radiosensitizers. Most of these trials consistently showed superior survival with the use of neoadjuvant treatment in resected patients as compared to historical controls who only received surgical resection. However, the direct impact of this treatment modality on resection rates is difficult to quantify for several reasons. First, the preoperative imaging quality during that time was limited in determining resectability. Second, even in cases where resectability status was based on laparotomy, there was institutional and surgeon variability with regards to expertise and definitions of resectability. While most of these studies demonstrated safety and feasibility, some showed survival comparable to that of studies involving adjuvant therapy. One such study by Hoffman et al. in 1995 included patients with both unresectable and resectable pancreatic cancers of adenocarcinoma and adenosquamous histology [@b17]. Patients received preoperative 5-FU plus MMC with concurrent radiotherapy. The resection rate for all patients was 32% with resected patients having a reported median survival of 45 months; which is almost twice as long as reported in other studies. Promising as these results appear, it is hard to apply data from such small, single arm, single institution studies due to inherent selection bias and the heterogeneity of the study population.

In the decade following, gemcitabine-based neoadjuvant combinations gained popularity due to the positive findings reported by Burris and colleagues in the metastatic setting with regards to clinical benefit as well as a modest survival advantage [@b18]. As a result of that latter study, gemcitabine received FDA approval and has become an established standard of care in advanced disease and in the adjuvant setting. The most frequently used neoadjuvant combinations were gemcitabine with or without an additional agent (including radiotherapy in some studies). The resection rate was noted to be variable depending on the initial resectability status of the patients enrolled. In the earlier trials, the overall resection rate after neoadjuvant therapy for patients who were deemed to have resectable disease upfront ranged from 50% to 70%. For those patients judged to be unresectable at the time of enrollment, the overall resection rate after neoadjuvant treatment ranged from 5% to 30%. More recent trials have shown an improved trend in both resection rates and survival for patients resected after preoperative treatment. In the modern era of studies, patients initially deemed resectable have resection rates in the 60--80% range with OS improving from 20 to 30 months for those patients receiving preoperative therapy. However, most of these studies were single institution or retrospective in design.

In an initial phase II trial from MD Anderson Cancer Center, 86 patients with resectable, histologically proven adenocarcinomas of pancreatic head or uncinate process were treated with neoadjuvant therapy [@b19]. These patients underwent preoperative treatment with gemcitabine weekly for 7 weeks along with 30 Gy of EBRT over 2 weeks. The overall resection rate was 74%, (57/64 patients had R0 resections) with median survival of those patients undergoing resection noted to be 34 months. However, the majority of cases that relapsed did so with distant metastases. Therefore, in an attempt to improve the OS, Varadhachary and colleagues incorporated more systemic therapy by adding induction chemotherapy with gemcitabine plus cisplatin for four doses followed by chemoRT using gemcitabine weekly with 30 Gy EBRT [@b20]. Of the 90 patients enrolled, 79 were able to complete neoadjuvant treatment. The overall resection rate for these 79 patients was 66% (51/52 patients had R0 resections) with median OS for those resected being 31 months. Memorial Sloan-Kettering Cancer Center treated 38 patients with gemcitabine with oxaliplatin for four cycles neoadjuvantly [@b21]. Thirty-five patients (92%) completed neoadjuvant chemotherapy; 27 were ultimately resected (72%) and 23 (60.5%) were able to complete all planned treatments including additional adjuvant chemotherapy. Median OS was 27.2 months suggesting improvement in ability to complete the delivery of multimodality therapy. Additional prospective and retrospective neoadjuvant trials are summarized in Table[2](#tbl2){ref-type="table"}.

###### 

Neoadjuvant therapy trials in pancreatic adenocarcinoma

  Author/year                    Location                                                            Resectability (n)                                        Neoadjuvant therapy                                                                                                            Resection rate                                       Median OS unresected                                   Median OS resected
  ------------------------------ ------------------------------------------------------------------- -------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------ ---------------------------------------------------- ------------------------------------------------------ -----------------------------------
  **Prospective studies**                                                                                                                                                                                                                                                                                                                                                                                
   Weese JL 1990 [@b33]          Head (14), Body (1)                                                 R = 15                                                   5-FU + Mitomycin-C + EBRT                                                                                                      ORR = 60%                                            7 month                                                NR
                                                                                                                                                                                                                                                                                             R0 = 60%                                                                                                    
   Coia LR 1994 [@b34]           Pancreatic head/body (27) *Duodenum (4)*                            R = 10                                                   5-FU + Mitomycin-C + EBRT                                                                                                      ORR = 55% (48% panc) R0 = 49%                        Pancreatic cancer only 15% 1-year                      Pancreatic cancer only 60% 1-year
                                                                                                                                                                                                                                                                                             UR = 21 (all panc)                                                                                          
   Hoffman JP 1995 [@b17]        Head/body/tail adenosquamous included                               R = 21                                                   5-FU + Mitomycin-C + EBRT                                                                                                      ORR = 32%                                            NS                                                     45 month
                                                                                                     UR = 13                                                                                                                                                                                 R0 = 29%                                                                                                    
   Kamthan AG 1997 [@b35]        Head/body/tail                                                      UR = 35                                                  5-FU + Streptozocin + Cisplatin + EBRT → 5FU/leucovorin                                                                        ORR = 15%                                            All patients = 15 month                                31 month
                                                                                                                                                                                                                                                                                             R0 = NS                                                                                                     
   Hoffman JP 1998 [@b36]        Head/body/tail                                                      R = 53                                                   5-FU + Mitomycin-C + EBRT                                                                                                      ORR -- 45%                                           No surg -- 5 month, Surg and no resection -- 8 month   15 month
                                                                                                                                                                                                                                                                                             R0 -- 32%                                                                                                   
   Staley CA 1996 [@b37]         Head                                                                R = 39                                                   5-FU + EBRT                                                                                                                    ORR = 100%                                           NA                                                     19 month
                                                                                                                                                                                                                                                                                             R0 = 82%                                                                                                    
   Pisters PW 1998 [@b38]        Head                                                                R = 35                                                   5-FU + rapid fractionation EBRT. Additional intraop RT only if PD                                                              ORR = 57%                                            7 month                                                25 month
                                                                                                                                                                                                                                                                                             R0 = 51%                                                                                                    
   Bajetta E 1999 [@b39]         Head/body/tail                                                      UR = 32                                                  5-deoxyfluridine/leucovorin + EBRT                                                                                             ORR = 16%                                            All patients = 9 month                                 NS
                                                                                                                                                                                                                                                                                             R0 = 16%                                                                                                    
   Snady H 2000 [@b40]           Head/body/tail                                                      UR = 68                                                  5-FU + Streptozocin + Cisplatin + EBRT                                                                                         ORR = 29%                                            21 month                                               32 month
                                                                                                                                                                                                                                                                                             R0 = 28%                                                                                                    
   Wanebo HJ 2000 [@b41]         Head/body                                                           R = 5                                                    5FU + Cisplatin + EBRT                                                                                                         ORR = 64%                                            9 month                                                19 month
                                                                                                     UR = 6                                                                                                                                                                                  R0 = 64%                                                                                                    
                                                                                                     Unk = 3                                                                                                                                                                                                                                                                                             
   Pipas JM 2001 [@b42]          Head/body/tail                                                      UR = 21                                                  Gemcitabine + EBRT (Phase I study)                                                                                             ORR = 24%                                            NS                                                     NS
                                                                                                                                                                                                                                                                                             R0 = 24%                                                                                                    
   Wolff RA 2001 [@b43]          Head                                                                UR = 18                                                  Gemcitabine + EBRT (Phase I study)                                                                                             ORR = 5%                                             All patients = 6 month                                 NS
                                                                                                                                                                                                                                                                                             R0 = 5%                                                                                                     
   De Lange SM 2002 [@b44]       Head/body/tail                                                      UR = 24                                                  Gemcitabine + EBRT → Gemcitabine                                                                                               ORR = 4%                                             All patients = 10 month                                NS
                                                                                                                                                                                                                                                                                             R0 = 4%                                                                                                     
   Epelbaum R 2002 [@b45]        Head/body/tail                                                      UR = 20                                                  Gemcitabine → Gemcitabine + EBRT                                                                                               ORR = 15%                                            All patients = 8 month                                 24 month
                                                                                                                                                                                                                                                                                             R0 = 10%                                                                                                    
   Pisters PW 2002 [@b46]        Head/uncinate process                                               R = 35                                                   Paclitaxel + EBRT Additional intraop RT only if PD                                                                             ORR = 57%                                            All patients = 12 month                                19 month
                                                                                                                                                                                                                                                                                             R0 = 40%                                                                                                    
   Al-Sukhun S 2003 [@b47]       Head/body/tail                                                      UR = 20                                                  Cisplatin + 5-FU + Cytarabine → Caffeine → 5-FU + EBRT                                                                         ORR = 15%                                            All patients = 13 month                                24 month
                                                                                                                                                                                                                                                                                             R0 = NS                                                                                                     
                                                                                                                                                                                                                                                                                             R1 = NS                                                                                                     
   Brunner TB 2003 [@b48]        Head/body/tail                                                      UR = 30                                                  Cisplatin + Gemcitabine + EBRT                                                                                                 ORR = 31%                                            11 month                                               18 month
                                                                                                                                                                                                                                                                                             R0 = 28%                                                                                                    
   Joensuu 2004 [@b49]           Head/body/tail                                                      R = 28                                                   Gemcitabine + EBRT                                                                                                             ORR = 71%                                            NS                                                     NS
                                                                                                                                                                                                                                                                                             R0 = 71%                                                                                                    
   Moutardier V 2004 [@b50]      Head/body                                                           R = 61                                                   5-FU + Cisplatin + EBRT                                                                                                        ORR = 65%                                            All patients = 13 month                                26.6 month
                                                                                                                                                                                                                                                                                             R0 = 60%                                             UR = 8.6 month                                         
   Magnino A 2005 [@b51]         Head/body/tail                                                      UR = 23                                                  Gemcitabine + EBRT                                                                                                             ORR = 26%                                            All patients = 14 month                                20 month
                                                                                                                                                                                                                                                                                             R0 = 22%                                             UR = 12 month                                          
   Pipas JM 2005 [@b52]          Head/body                                                           R = 4                                                    Docetaxel + Gemcitabine → Gemcitabine + EBRT                                                                                   ORR = 71%                                            All patients = 14 month                                NS
                                                                                                     BR = 7                                                                                                                                                                                  R0 = 54%                                                                                                    
                                                                                                     UR = 13                                                                                                                                                                                                                                                                                             
   Mornex F 2006 [@b53]          Head/body/tail                                                      R = 41                                                   5-FU + Cisplatin + EBRT                                                                                                        ORR = 63%                                            All patients = 9.4 month                               11.7 month
                                                                                                                                                                                                                                                                                             R0 = 51%                                                                                                    
   Talamonti MS 2006 [@b54]      Head/body/tail                                                      R = 20                                                   Gemcitabine → Gemcitabine + EBRT                                                                                               ORR = 85%                                            All patients = 18 month                                26 month
                                                                                                                                                                                                                                                                                             R0 = 80%                                                                                                    
   Wilkowski R 2006 [@b55]       Head/body/tail                                                      UR = 32                                                  Gemcitabine + 5-FU + EBRT → Gemcitabine + Cisplatin                                                                            ORR = 18%                                            All patients = 13.6 month                              16.4 month
                                                                                                                                                                                                                                                                                             R0 = 12%                                                                                                    
   Desai SP 2007 [@b56]          Head/body/tail/mets                                                 R = 12                                                   Gemcitabine + Oxaliplatin + EBRT                                                                                               ORR = 16%                                            UR/metastatic = 9.1 month                              20.8 month
                                                                                                     UR = 29                                                                                                                                                                                 R0 = 16%                                                                                                    
                                                                                                     ^\*^metastatic = 3                                                                                                                                                                                                                                                                                  
   Palmer DH 2007 [@b57]         Head of pancreas by radiology                                       R = 50                                                   Randomized phase II study: (A)Gemcitabine (*N* = 24) (B)Gemcitabine + Cisplatin (*N* = 26)                                     ORR = 38% in A and 70% in BR0 = 75% in both          All patients (A) = 9.9 month, (B) = 15.6 month         28.4 month
                                 Sp resection 3 pts had malignancy other than pancreatic adenoca                                                                                                                                                                                                                                                                                                         
   Evans DB 2008 [@b19]          Head/uncinate process                                               R = 86                                                   Gemcitabine + EBRT                                                                                                             ORR = 74%                                            All patients = 22.7 month                              34 month
                                                                                                                                                                                                                                                                                             R0 = 66%                                             UR = 7 month                                           
   Heinrich S 2008 [@b58]        Head                                                                R = 28                                                   Gemcitabine + Cisplatin                                                                                                        ORR = 86%                                            NS                                                     26.5 month
                                                                                                                                                                                                                                                                                             R0/R1 = NS                                                                                                  
   Le Scodan 2008 [@b59]         Head/body/tail                                                      R = 41                                                   5-FU + Cisplatin + EBRT                                                                                                        ORR = 63%                                            All patients = 9.4 month                               11.7 month
                                                                                                                                                                                                                                                                                             R0 = 51%                                                                                                    
   Marti JL 2008 [@b60]          Head/body/tail                                                      UR = 23                                                  Gemcitabine + Cisplatin (*n* = 26) → Gemcitabine + Cisplatin + EBRT (*n* = 18)                                                 ORR = 15%                                            All patients = 13 month                                17 month
                                                                                                     BR = 3                                                                                                                                                                                  R0 = 12%                                                                                                    
   Small W 2008 [@b61]           Head/body/tail                                                      R = 16                                                   Gemcitabine + EBRT                                                                                                             ORR = 81% for R, 33% for BR, 7% for UR               All patients 1-year 73%                                NS
                                                                                                     BR = 9                                                                                                                                                                                                                                                                                              
                                                                                                     UR = 14                                                                                                                                                                                                                                                                                             
   Varadhachary GR 2008 [@b20]   Head/uncinate                                                       R = 90                                                   Gemcitabine + Cisplatin → Gemcitabine + EBRT                                                                                   ORR = 58%                                            All patients 17.4 month, UR 10 month                   31 month
                                                                                                                                                                                                                                                                                             R0 = 56%                                                                                                    
   Bjerregaard JK 2009 [@b62]    Head/body/tail                                                      UR = 63                                                  UFT + folinic acid + EBRT                                                                                                      ORR = 17%                                            8.8 month                                              46 month
                                                                                                                                                                                                                                                                                             R0 = 17%                                                                                                    
   Choi M 2010 [@b63]            Head/body/tail                                                      UR = 20                                                  Cisplatin + Cytarabine + Caffeine + 5-FU → 5-FU + EBRT                                                                         ORR = 15%                                            All patients = 13.7 month                              24.3 month
                                                                                                                                                                                                                                                                                             R0 = NS                                                                                                     
   Laurent S 2009 [@b64]         Head/body/tail ^\*^also had biliary cancer but outcomes separated   UR = 17                                                  Gemcitabine + Oxaliplatin → Gemcitabine + Oxaliplatin + EBRT                                                                   ORR = 17%                                            All patients = 17 month                                NS
                                                                                                                                                                                                                                                                                             R0 = 17%                                                                                                    
   Maximous DW 2009 [@b65]       Head/body/tail                                                      R = 25                                                   Gemcitabine + EBRT                                                                                                             ORR = 32%                                            All patients = 12 month                                1-year = 87%
                                                                                                                                                                                                                                                                                             R0 = NS                                              Unresected 1-year = 22%                                
   Turrini O 2010 [@b66]         Head/body/tail                                                      R = 34                                                   Docetaxel + EBRT                                                                                                               ORR = 50%                                            All patients = 15.5 month, unresected 11 month         32 month
                                                                                                                                                                                                                                                                                             R0 = 50%                                                                                                    
   Landry J 2010 [@b67]          Head/body/tail                                                      R = 10                                                   Randomized phase II: \[A\] Gemcitabine + EBRT (*n* = 10) \[B\] Gemcitabine + Cisplatin + 5-FU → 5-FU + EBRT (*n* = 11).        ORR, A = 30%, B = 18%                                All patients, arm A = 19.4 month, arm B = 14.2 month   22 month in both A and B
                                 4 with "other" histology                                            UR = 8                                                                                                                                                                                                                                                                                              
                                                                                                     ? = 3                                                                                                                                                                                                                                                                                               
                                                                                                                                                              All patients got adjuvant Gemcitabine                                                                                                                                                                                                      
   Sahora K 2010 [@b68]          Head/body/tail                                                      UR = 18                                                  Gemcitabine + Oxaliplatin                                                                                                      ORR = 39%                                            12 month                                               22 month
                                                                                                     BR = 15                                                                                                                                                                                 R0 = 27%                                                                                                    
                                                                                                                                                                                                                                                                                             R1 = 9%                                                                                                     
  Lee JL 2012 [@b69]             Head/body/tail                                                      BR = 18                                                  Dose Dense Gemcitabine + Capecitabine                                                                                          PR = 18.6%                                           13.1 month                                             23.1 month
                                                                                                     UR = 25                                                                                                                                                                                 SD = 69.8%                                                                                                  
                                                                                                                                                                                                                                                                                             R0 = 82% out of 17 resected                                                                                 
                                                                                                                                                                                                                                                                                             R1 = 18%                                                                                                    
   Pipas JM 2012 [@b70]          Head/body/tail                                                      R = 4                                                    Cetuximab load then                                                                                                            ORR = 91% (PR = 30%)                                 10 month                                               24.3 month
                                                                                                     BR = 23                                                  Cetuximab + Gemcitabine + EBRT                                                                                                                                                                                                             
                                                                                                     UR = 6                                                                                                                                                                                  R0 = 92% out of 70% resected                                                                                
   Satoi S 2012 [@b71]           Head/body/tail                                                      R = 23                                                   S1 + EBRT                                                                                                                      ORR = 88% (PR = 18%)                                 NS                                                     NS
                                                                                                     BR/UR = 7                                                                                                                                                                               R0 = 93%                                                                                                    
   Chao YJ 2014 [@b72]           Head/body/tail                                                      UR=41                                                    Gemcitabine+5FU+Oxaliplatin+Thalidomide or Gemcitabine+5FU+Oxaliplatin+Sunitinib or Gemcitabine-based Chemoradiation           RR=51.2% (CR=5%, PR=46%)R0 = 31%, R1 = 5%, R2 = 2%   9 month                                                21 month
   Golcher H 2014 [@b73]         Head                                                                R = 73                                                   Primary surgery or Gemcitabine + Cisplatin + EBRT                                                                              4 PR, 8 SD in treatment group                        NR                                                     18.9 versus 25 month
                                                                                                                                                                                                                                                                                             R0 = 48 and 52%                                                                                             
   O'Reilly EM 2014 [@b21]       Head/body/tail                                                      R = 38                                                   Gemcitabine + Oxaliplatin                                                                                                      PR = 10.5%                                           27.2 month (all)                                       NS
                                                                                                                                                                                                                                                                                             SD = 73.7%                                                                                                  
                                                                                                                                                                                                                                                                                             R0/R1 = 77%                                                                                                 
  **Retrospective studies**                                                                                                                                                                                                                                                                                                                                                                              
   White RR 2001 [@b74]          Pancreatic head/body/tail                                           R = 53,                                                  5-FU-based chemotherapy + EBRT                                                                                                 53% in R group, 19% in BR or UR                      NS                                                     Actuarial 2 year OS 32%
                                                                                                     BR or UR = 58                                            \[5FU alone (n = 71), w mitomycin (n = 17), with cisplatin (n = 4), combination of 5Fu/mito/cis (n = 13), oral 5FU (n = 6)\]                                                                                                               
   Aristu J 2003 [@b75]          head/body/tail,                                                     UR = 49                                                  Chemotherapy + EBRT (one of 3 chemo):                                                                                          ORR = 19%                                            10 month                                               22 month
                                                                                                                                                              Cisplatin + 5FU                                                                                                                                                                                                                            
                                                                                                                                                              Cisplatin + 5FU +/− Paclitaxel                                                                                                                                                                                                             
                                                                                                                                                              Gemcitabine + Docetaxel.                                                                                                                                                                                                                   
                                                                                                                                                              (23 UR pts got additional EBRT)                                                                                                                                                                                                            
   Calvo FA 2004 [@b76]          Head/body                                                           R = 15                                                   Tegafur + EBRT                                                                                                                 ORR = 60%                                            8 month (UR) 17 month (all)                            23 month
                                                                                                                                                                                                                                                                                             R0 = 46% overall                                                                                            
   Sa Cunha 2005 [@b77]          Head/body/tail                                                      UR = 61                                                  5-FU + Cisplatin + EBRT                                                                                                        ORR = 21%                                            11 month (nonresponders)                               28 month
   Brown KM 2008 [@b78]          Head/body/tail                                                      BR = 13                                                  Chemo + EBRT (chemo):                                                                                                          ORR-100%                                             NS                                                     NS
                                                                                                                                                              5FU (*n* = 3), Gemcitabine (*n* = 9), Capecitabine + Bevacizumab (*n* = 1)                                                     R0 = 85%                                                                                                    
   Allendorf JD 2008 [@b79]      Head/body/tail                                                      UR = 78 (preop CRT) versus R = 167 (upfront resection)   Gem + Taxotere + Xeloda (81% of pts)                                                                                           ORR = 76%                                            16.6 month upfront resection                           17.7 month resected sp CRT
                                                                                                                                                              75% pts also got EBRT                                                                                                          R0 = 84.7% of resected                                                                                      
   Golcher H 2008 [@b80]         Head/body                                                           UR = 121 (preop CRT)                                     (5FU + Mitomycin) or (Gemcitabine + Cisplatin) + EBRT                                                                          ORR = 17%                                            21 month upfront resection                             54 month resected sp CRT
                                                                                                     versus R = 58 (upfront resection)                                                                                                                                                       R0 = 90% of 17%                                                                                             
   Turrini O 2009 [@b81]         Head                                                                BR = 49, UR = 15                                         5-FU + Cisplatin + EBRT                                                                                                        ORR = 14%                                            13 month (UR), 14 month (all)                          24 month
   Stokes JB 2011 [@b82]         Head/body/tail                                                      BR = 34                                                  Capecitabine + EBRT                                                                                                            ORR = 46%                                            NS                                                     23 month
                                                                                                                                                                                                                                                                                             R0 = 75% of 46%                                                                                             
   Patel M 2011 [@b83]           Head/body/tail                                                      BR = 17                                                  Gemcitabine + Taxotere + Capecitabine → 5-FU + IMRT                                                                            ORR = 53%                                            15.6 month (all)                                       NS
                                                                                                                                                                                                                                                                                             R0 = 89% of 53%                                                                                             
   Arvold ND 2012 [@b22]         Head/body/tail                                                      BR = 24                                                  5FU or Capecitabine + EBRT                                                                                                     PR = 30%                                             13.2 mo                                                19.4 month
                                                                                                     UR = 46                                                                                                                                                                                 R0 = 79% of 20%                                                                                             
   Sho M 2012 [@b84]             NR                                                                  R = 61                                                   Gemcitabine + EBRT                                                                                                             R0 92% versus 52% controls                           28 month (neoadjuvant)                                 NS
                                                                                                     BR = 71                                                                                                                                                                                                                                                                                             
   Strobel O 2012 [@b23]         Head/body/tail                                                      R = 120                                                  (5FU, Gemcitabine, or Cetuximab-based) Chemoradiation or Chemotherapy                                                          R0 35%, R1 50.8%, R2 13.3% of 46.7% resected         9 month                                                13 month
                                                                                                     UR = 137                                                                                                                                                                                                                                                                                            
   Boone BA 2013 [@b25]          Head/body/tail                                                      BR = 12                                                  FOLFIRINOX + EBRT                                                                                                              R0 = 33%                                             NS                                                     NS
                                                                                                     UR = 13                                                                                                                                                                                                                                                                                             
   Faris JE 2013 [@b26]          Head/uncinated/tail                                                 UR = 22                                                  FOLFIRINOX +/− 5FU or Capecitabine + EBRT                                                                                      PR = 27.3%                                           NS                                                     NS
                                                                                                                                                                                                                                                                                             SD = 72.7%                                                                                                  
                                                                                                                                                                                                                                                                                             R0 = 23%                                                                                                    
   Papavasiliou P 2014 [@b24]    Head/uncinate                                                       NS                                                       Gemcitabine or 5FU + EBRT                                                                                                      RR = NS                                              22 month (all)                                         NS
                                                                                                                                                                                                                                                                                             R0 = 68.5%, R1 = 30.6%, R2 = 0.9%                                                                           
   Rose JB 2014 [@b32]           Head/body/tail                                                      BR = 64                                                  Gemcitabine + Docetaxel                                                                                                        R0 = 87% of 61%                                      15.4 month                                             NR
                                                                                                                                                                                                                                                                                                                                                  23.6 month (all)                                       

R, resectable; BR, borderline resectable; UR, unresectable; UNK, unknown; ORR, overall resection rate; R0, complete microscopically negative; R1, positive margin; PD, pancreaticoduodenectomy; EBRT, external beam radiotherapy; OS, overall survival; NS, not specified; NR, not reached; NA, not applicable; 5-FU, 5-Fluorouracil; FOLFIRINOX, Folinic acid, 5-Fluorouracil, Irinotecan, Oxaliplatin; C, cycle; →, followed by.

Given the risk of incomplete resection, neoadjuvant chemotherapy may similarly improve outcomes in borderline-resectable pancreatic cancer. In a retrospective report from Massachusetts General Hospital, 46 patients with unresectable and 24 patients with borderline-resectable disease were treated with neoadjuvant fluoropyrimidine-based chemoRT. Approximately 30 of these patients additionally received gemcitabine-based chemotherapy sequenced before the chemoRT. Compared with chemoRT alone, the use of neoadjuvant chemotherapy before chemoRT achieved improved median overall (18.7 vs. 12.4 months; *P* = 0.02) and progression-free survival (11.4 vs. 6.7 months; *P* = 0.02) [@b22].

The development of novel targeted or more contemporary cytotoxic therapeutics in metastatic pancreatic cancer was also investigated in the neoadjuvant setting. In a retrospective large single center study by Strobel and colleagues, 257 patients received neoadjuvant chemotherapy or chemoradiation [@b23]. Only 120 (46.7%) underwent successful resection. Median postoperative survival was highest at R0 resected patients (24.6 months) compared to R1 (11.9 months) and R2 (8.9 months) demonstrating that margin status at surgery is still a major determinant of outcome, even with contemporary neoadjuvant therapy. The incorporation of FOLFIRINOX chemotherapy in the neoadjuvant setting has been explored in relatively small pilot studies. Boone and colleagues at the University of Pittsburgh treated 21 unresectable and borderline-resectable patients with this regimen. Two patients (9%) could not tolerate treatment and another three (14%) had disease progression. Overall, seven patients ultimately underwent resection of which 2 (10%) were initially unresectable and were felt to have been converted. Five (24%) of the treated and resected patients had significant histopathological response [@b24]. Massachusetts General investigators treated 22 locally advanced pancreatic cancer patients in this manner with five of 22 patients achieving R0 resections after completing FOLFIRINOX, 5FU-based chemoradiation and surgical resection. However, three had distant recurrence and toxicity was significant with this approach [@b25].

While it is clear from the published studies that neoadjuvant therapy for pancreatic cancer appears feasible, the demonstrated benefits have been inconsistent. One of the primary limitations of these studies has been the use of historical controls as a comparison group. Over the intervening years, imaging technology has become increasingly accurate in delineating vessel involvement by pancreatic cancer, which is a major barrier to successful surgical resection. Indeed, such stage migration will, by definition, improve the apparent survival of patients newly diagnosed with both resectable as well as locally advanced pancreatic cancer. Similarly, advances in surgical techniques with more sophisticated vascular reconstruction capabilities, have also impacted the ability to obtain complete resections. However, it is not clear if complete resection in these borderline or previously unresectable patients with the use of modern vascular reconstruction techniques affords a similar long-term benefit as a complete resection in an initially clearly resectable patient. Another limitation includes an evolving definition of resectable disease. Surgical perspective by the treating physician adds a nongeneralizable bias to patient selection in regards to generating a homogenous treatment group as well as appropriate control matching. Only recently has a consistent definition been applied to studies, thus allowing cross-study comparisons. The summary data of neoadjuvant treatments (Table[2](#tbl2){ref-type="table"}) inventories the outcomes of patients organized by resectable, borderline resectable, and unresectable disease.

Further confounding the response of neoadjuvant treatment was a publication by the MD Anderson group. These authors reported that routine imaging does not reflect anatomic-pathologic changes associated with the effectiveness of neoadjuvant therapy [@b26]. This retrospective study reviewed 122 patients with borderline-resectable pancreatic adenocarcinoma who had restaging of their disease after neoadjuvant treatment. Even though only 12% of patients met the RECIST imaging criteria for a partial response and only one patient (0.8%) was officially downstaged to resectable, (69% had stable disease and 19% had progressive disease), 66% of the patients were able to undergo pancreaticoduodenectomy. Median OS for patients who underwent surgery was 33 versus 12 months for those who did not.

In an attempt to determine aggregate outcome measures; Gillen et al. performed a systematic review on neoadjuvant therapy trials in pancreatic cancer [@b27]. This meta-analysis looked at more than 100 neoadjuvant trials published since 1980, despite the heterogeneity of patients enrolled and regimens used. Of those patients considered resectable at diagnosis, approximately 74% went on to have surgical resection after neoadjuvant treatment with an R0 resection rate of 82%. Median survival in this group was 23.3 months (range 12--54 months) with 2-year survival of 47%. These survival results are comparable to patients who had initial surgery first followed by adjuvant therapy. Among the patients that were deemed to be initially unresectable, the overall resection rate after neoadjuvant treatment was 33% with R0 resection rate of 79%. The median OS was 20.5 months (range 9--62 months) with a 2-year survival of 50% for this group. Median survival, however, was only 10.2 months for those patients whose disease remained unresectable despite neoadjuvant treatment, which is similar to patients who were treated with palliative intentions (median survival 8--12 months). Despite the data, no standard regimen or sequence of treatment could be conclusively determined.

Further adding to the published data on this topic, Artinyan and colleagues conducted a population-based cohort series [@b28]. Using the California Cancer Surveillance Program, 458 patients with pancreatic adenocarcinoma who underwent surgical resection and received systemic chemotherapy between 1987 and 2006 were retrospectively analyzed. Neoadjuvant treatment was delivered in about 9% of the patients and adjuvant treatment given in 91% cases. Patient characteristics such as age, gender, and tumor size were similar between the two groups; however, data on performance status or co-morbidities were not reported. There was a significantly lower rate of positive pathologic lymph nodes in the neoadjuvant group (45% vs. 65%) despite a higher rate of extra-pancreatic tumor extension. The neoadjuvant group also had significantly better OS compared with the adjuvant group (median survival, 34 vs. 19 months). While there are obvious limitations of a population-based cohort study, it is clear that only a small percentage of patients in that clinical practice environment received neoadjuvant treatment. Thus, such patients are likely highly selected individuals.

Nonetheless, this summative data combined with the systematic review and meta-analyses suggest that neoadjuvant therapy can be conducted safely in select patients and may possibly benefit a subset of those with resectable and borderline-resectable disease. By introducing early systemic treatment to combat distant relapses coupled with avoidance of a radical surgical resection in patients whose disease is biologically aggressive, neoadjuvant treatment offers many advantages. However, the magnitude of the impact has yet to be demonstrated or validated in a randomized controlled trial.

Final Thoughts
==============

Despite the opportunity to improve survival by incorporating systemic treatment in the neoadjuvant setting and better selection of patients with truly localized cancer, survival in this dreaded disease still remains modest. The key to significantly impacting survival, short of prevention, would be the identification of therapeutic interventions tailored to the patient, which can overcome the inherent resistance mechanisms evoked by the cancer. To achieve this goal of appropriate patient selection based on patient and disease characteristics and to optimize their chance of receiving the optimal medical, radiation and surgical treatment, a multidisciplinary, collaborative approach to the care of each and every patient with pancreatic adenocarcinoma is imperative. Despite all the strides in various oncologic disciplines the ability to offer a cure to most patients remains unachievable. Perhaps the best case for neoadjuvant multidisciplinary approach is to rapidly test novel hypotheses and the effects of various treatments on the tumor and the surrounding microenvironment. A neoadjuvant platform could gain insights into the tumor biology, which may ultimately hold the key to achieving cure for most, if not all patients afflicted with this deadly disease. However, this requires adequate tissue acquisition of the tumor tissue to confirm the initial diagnosis. Increased cytologic yield through endoscopically obtained core biopsies or circulating tumor cells will be required in the future to fully realize the molecular characterization and personalized therapeutics potential.

The less than ideal response to cytotoxic and targeted therapies is evident in the abundant trials in the metastatic setting that have consistently failed to demonstrate a statistically significant or clinically meaningful advantage over single agent gemcitabine (Table[3](#tbl3){ref-type="table"}). Only recently have FOLFIRINOX and gemcitabine with nab-paclitaxel raised the bar [@b29]--[@b31]. While the use of two or three cytotoxic drugs showed significant survival advantage over gemcitabine alone (median OS 11.1 vs. 6.8 months; *P* \< 0.001) in patients with metastatic disease, toxicities limit use to select patients with excellent performance status and no major comorbidities.

###### 

Outcomes of selected randomized controlled clinical trials in metastatic pancreatic adenocarcinoma

  Reference                           Treatment                                                                         Total *N*   Median survival (month)   *P*-value
  ----------------------------------- --------------------------------------------------------------------------------- ----------- ------------------------- ----------------------
  Bramhall SR, BJC 2002 [@b85]        Gemcitabine +/− Marimastat                                                        239         5.4 versus 5.5            0.95
  Berlin JD, JCO 2002 [@b86]          Gemcitabine +/− 5-FU                                                              322         5.7 versus 6.5            0.09
  Colucci G, Cancer 2002 [@b87]       Gem versus Gem + Cisplatin                                                        107         5 versus 7.5              0.43
  Rocha Lima CM, JCO 2004 [@b88]      Gemcitabine +/− Irinotecan                                                        342         6.3 versus 6.6            0.78
  Van Custem E, JCO 2004 [@b89]       Gemcitabine +/− Tipifarnib                                                        688         6.1 versus 6.4            0.75
  Louvet C, JCO 2005 [@b90]           Gemcitabine +/− Oxaliplatin                                                       313         7.1 versus 9              0.13
  Oettle H, Ann Oncol 2005 [@b91]     Gemcitabine +/− Premetexed                                                        565         6.3 versus 6.2            0.84
  Abou-Alfa GK, JCO 2006 [@b92]       Gemcitabine +/− Exatecan                                                          349         6.2 versus 6.7            0.52
  Heinemann V, JCO 2006 [@b93]        Gem versus Gem+Cisplatin                                                          195         6 versus 7                0.15
  Stathopoulous GP, BJC 2006 [@b94]   Gemcitabine +/− Irinotecan                                                        145         6.4 versus 6.5            0.97
  Herrmann R, JCO 2007 [@b95]         Gemcitabine +/− Capecitabine                                                      319         7.2 versus 8.4            0.23
  Moore MJ, JCO 2007 [@b96]           Gemcitabine +/− Erlotinib                                                         569         5.9 versus 6.3            **0.03**
  Poplin E, JCO 2009 [@b97]           Gemcitabine versus fixed dose rate Gemcitabine versus Gemcitabine + Oxaliplatin   832         4.9 versus 6 versus 5.7   **0.04**
                                                                                                                                                              0.22
  Van Custem E, JCO 2009 [@b98]       Gemcitabine+Erlotinib +/− Bevacizumab                                             301         6.0 versus 7.1            0.20
  Kindler HL, JCO 2010 [@b99]         Gemcitabine +/− Bevacizumab                                                       602         5.9 versus 5.8            0.95
  Philip PA, JCO 2010 [@b100]         Gemcitabine +/− Cetuximab                                                         745         5.9 versus 6.3            0.23
  Conroy T, NEJM 2011 [@b24]          Gemcitabine versus FOLFIRINOX                                                     342         6.8 versus 11.1           **\<0.001**
  Von Hoff, NEJM 2013 [@b101]         Gemcitabine +/− nab-paclitaxel                                                    861         8.5 versus 6.7            ***P***** \< 0.001**

5-FU, 5-fluorouracil; +/−, one arm with and one arm without the drug following the sign.

Bold indicates statistically significant.

Thus, the future of effective pancreatic cancer therapy must take into consideration not just the cancer, but also the interplay of the tumor microenvironment, the inherent biologic features that confer early metastatic potential to the cancer, the role of cancer stem cells in therapy resistance mechanisms, and novel gain of function mutations that may serve as new targets for therapeutic disruption. Only an adequately powered prospective study will be able to determine if neoadjuvant therapy provides a survival advantage for early stage pancreatic cancer patients. This study should randomize patients with borderline-resectable disease to the most effective systemic chemotherapy and/or chemoradiotherapy before or after surgery, and explore important outcomes such as relapse free survival and OS. Secondary end points should include resection rates, toxicity and surgical complications. At this moment, however, no such trial exists and neoadjuvant therapy should be conducted as part of an investigational program.
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